CA
NZ
UK
AU
IND
US
The randomized, double-blind, placebo-controlled study evaluated a single 100 µg dose of DT120 (lysergide) orally disintegrating tablet (ODT) in adult patients diagnosed with MDD. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in Montgomery–Åsberg Depression Rating Scale …
Under the terms of the agreement, AbbVie (NYSE: ABBV) will acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share in cash, representing a substantial premium to the company's previous closing price. The transaction has been unanimously approved by the boards of directors of both …
Nutriband Inc. (NASDAQ:NTRB) rose 6.21% in pre-market trading on June 22, reaching USD 3.08 after closing at USD 2.90 on June 18.
Under the terms of the transaction, CervoMed (NASDAQ: CRVO) agreed to sell 2,500,000 shares at a purchase price of $4.00 per share, generating approximately $10.0 million in gross proceeds before fees and expenses. The company stated that it plans to use the net proceeds …
The biggest story in biotechnology was undoubtedly AbbVie’s (NYSE: ABBV) agreement to acquire Apogee Therapeutics (NASDAQ: APGE) for approximately $10.9 billion in cash.
The transaction assigns Sarborg an implied valuation of approximately $638.3 million, a figure that has significantly altered perceptions of CDT Equity’s (NASDAQ: CDT) underlying asset value. Based on its ownership of 1,020 Sarborg shares, CDT’s stake is now estimated to be worth roughly $127.5 …
The standout result was the durability and magnitude of patient responses after one year of treatment. MoonLake Immunotherapeutics (NASDAQ: MLTX) reported that 67.2% of patients achieved HiSCR75, a key measure indicating a 75% reduction in inflammatory lesions. The outcome compares favorably with historical performance …
The transaction integrates Colospan’s proprietary CE-marked colorectal surgical device into Galmed Pharmaceuticals' (NASDAQ: GLMD) portfolio, providing the company with a commercial asset that has already secured reimbursement coding in Germany. Management believes the acquisition creates a pathway to initial revenue generation across European and …
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is trading at $8.32 pre-market June 22, up 3.35% from the June 18 close of $8.05. SELLAS is a late-stage clinical biopharmaceutical company developing novel cancer immunotherapies, with lead candidate galinpepimut-S (GPS), a peptide immunotherapy targeting the …
Definium Therapeutics, Inc. (NASDAQ: DFTX), formerly known as Mind Medicine (MindMed) Inc., is trading at $27.38 pre-market June 22, up 11.85% from the June 18 close of $24.48. Definium is a New York-based late-stage clinical biopharmaceutical company developing next-generation psychedelic-based therapeutics targeting underlying causes …
Please wait processing your request...